Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-62.33M |
| EBITDA | $-97.18M |
| Operating Margin | 0.00% |
| Return on Equity | -54.80% |
| Return on Assets | -32.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.13 |
| Price-to-Book | 1.57 |
| Price-to-Sales (TTM) | 478.26 |
| EV/Revenue | 416.34 |
| EV/EBITDA | -6.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $78.52M |
| Float | $47.28M |
| % Insiders | 0.60% |
| % Institutions | 114.50% |
Volatility is currently expanding
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY.
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform to be presented at ASGCT 2026 Appointed Laura Sepp-Lorenzino, Ph.D. to Board of Directors Cash, cash equivalents and investments of $227.6 million expected to provide operational runway into 2028 NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the first quarter 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LXEO and any ticker you trade — then tracks every position and per-strategy win rate.
